Pathway overview
A bone marrow or haematopoietic stem cell transplant (HSCT) replaces blood-forming stem cells after treatment designed for a specific blood cancer, immune disorder or other eligible condition. The transplant team—not the diagnosis alone—determines whether HSCT is appropriate and when it should occur.
Stem cells may be collected from peripheral blood, bone marrow or cord blood. In an autologous transplant, the patient’s own cells are returned after treatment. In an allogeneic transplant, cells come from a suitably matched donor and require careful compatibility, donor-safety and graft-versus-host disease planning.
HSCT is not a solid-organ transplant and it is not the same as unproven commercial ‘stem-cell therapy’. Patients should seek a hospital programme with the relevant adult or paediatric expertise, laboratory support, infection control and long-term follow-up.
Important distinctions
- Autologous HSCT
- The patient’s own stem cells are collected, stored and returned after high-dose treatment. There is no donor graft, but infection, organ toxicity and relapse remain important risks.
- Allogeneic HSCT
- Stem cells come from another person. HLA matching, donor evaluation, graft-versus-host disease prevention and immune recovery are central parts of planning.
- Cell source
- Peripheral blood, bone marrow and cord blood are different sources. The transplant team selects a source based on the disease, donor options and programme expertise.
- Adult and paediatric programmes
- Children and adults need age-appropriate specialist teams, dosing, supportive care and follow-up. A group-level claim should not be assumed to apply to every campus or age group.
How the evaluation pathway usually develops
- 01
Confirm diagnosis and treatment indication
The transplant team reviews pathology, bone marrow findings, genetics, disease stage, previous treatment and response to decide whether and when HSCT should be considered.
- 02
Assess fitness and infection risk
Evaluation commonly includes heart, lung, liver and kidney function, infection screening, dental review, medicines and psychosocial support.
- 03
Choose the transplant and cell-source strategy
For allogeneic HSCT, the team evaluates HLA matching and donor options. For autologous HSCT, it plans cell collection in relation to disease control and treatment.
- 04
Plan conditioning, admission and recovery
Patients should understand the conditioning regimen, expected hospital course, transfusion and infection support, early complications and the longer period of immune recovery.
Topics a hospital may evaluate
Requirements differ by person, programme, and jurisdiction. A licensed transplant team may consider:
- Confirmed diagnosis, disease status and response to previous treatment
- Whether autologous or allogeneic HSCT is indicated
- HLA typing, donor options and donor safety for an allogeneic pathway
- Heart, lung, liver and kidney function before conditioning
- Current or previous infections, vaccination history and infection-prevention planning
- Fertility, nutrition, psychological support and caregiver availability
- Post-transplant monitoring, graft-versus-host disease care and long-term follow-up
Questions to ask a licensed transplant hospital
- Does this campus provide the exact adult or paediatric HSCT programme required for this diagnosis?
- Which transplant type and cell source is the specialist team considering, and why?
- Which pathology, marrow, genetic and treatment-response records are required before review?
- How are donors identified, evaluated and protected in an allogeneic pathway?
- Which complications are managed on site, including graft-versus-host disease and serious infection?
- How long must the patient remain near the hospital, and how will follow-up continue after returning home?
